← Eichor
Condition: Borderline Resectable Pancreatic Adenocarcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Borderline Resectable Pancreatic Adenocarcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)
Phase 1/Phase 2 · 4 location(s) · Amsterdam UMC, location VUmc · NCT06384560Pancreatic Adenocarcinoma Neoadjuvant Chemotherapy Before Surgery
Phase 2 · 1 location(s) · Hamilton Health Sciences Corporation · NCT04452461PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 1 · 6 location(s) · PanTher Therapeutics · NCT06673017A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07671339Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC
Phase 3 · 1 location(s) · Sahlgrenska University Hospital · NCT06714604Targeted Pathway Inhibition in Patients With Pancreatic Cancer
EARLY_Phase 1 · 1 location(s) · OHSU Knight Cancer Institute · NCT04005690Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy
Phase N/A · 1 location(s) · Emory University · NCT06595160Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment
NA · 1 location(s) · British Columbia Cancer Agency · NCT06574620Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma
Phase 2 · 10 location(s) · Erasme University Hospital · NCT05083247NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial
Phase 2 · 1 location(s) · Roswell Park Cancer Institute · NCT06821997AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma
Phase N/A · 2 location(s) · Roswell Park Cancer Institute · NCT06320717Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
Phase 1 · 2 location(s) · Washington University School of Medicine · NCT06141031Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas
Phase 2 · 4 location(s) · Proton Collaborative Group · NCT02598349HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation
Phase 2 · 2 location(s) · Zhejiang University · NCT07240766PULSAR in Systemic Therapy for Pancreatic Cancer
Phase 2 · 1 location(s) · Samsung Medical Center · NCT07269626Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable
Phase 1/Phase 2 · 1 location(s) · Jonsson Comprehensive Cancer Center · NCT05688215A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05851924Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable
Phase 2 · 1 location(s) · Emory University · NCT06423326Dose-Painted Intensity Modulated Radiotherapy Pancreas (DP-IMRT Pancreas)
Phase 1/Phase 2 · 2 location(s) · Cancer Trials Ireland · NCT06024824A Cohort Study on ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer
Phase N/A · 2 location(s) · Ruijin Hospital · NCT07080021Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer
Phase N/A · 1 location(s) · Umeå University · NCT05356039Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
Phase 2 · 1 location(s) · Susan E. Bates · NCT05241249Safety of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma
NA · 1 location(s) · Capital Health System, Inc · NCT04998552Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Phase 2 · 1 location(s) · Wake Forest University Health Sciences · NCT0582506624BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
Phase 2 · 1 location(s) · Dartmouth-Hitchcock Medical Center · NCT07043270
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.